Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

ABSTRACT:

Introduction

The vast majority of tobacco smokers seeking to quit will relapse within the first month of abstinence. Currently available smoking cessation agents have limited utility in increasing rates of smoking cessation and in some cases there are notable safety concerns related to their use. Hence, there is a pressing need to develop safer and more efficacious smoking cessation medications.

Methods

Here, we provide an overview of current efforts to develop new pharmacotherapeutic agents to facilitate smoking cessation, identified from ongoing clinical trials and published reports.

Results

Nicotine is considered the major addictive agent in tobacco smoke, and the vast majority of currently available smoking cessation agents act by modulating nicotinic acetylcholin

SUBMITTER: Harmey D 

PROVIDER: S-EPMC3611986 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature